Pricing Log in Create free account
Wednesday 4 November 2026 Export AUTL’s income statement to Excel — free account

Autolus Therapeutics PLC Sponsored ADR

AUTL Healthcare Biotechnology

Autolus Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $75.4 million, up 644.9% from fiscal 2024.

Revenue
+118.4%
EPS
+16.7%
Free cash flow
+67.6%

Quarter to June 2026, against a year earlier

1.38 0.04 −2.82%
Market cap
$376.6M
P/E
0.0×
Fwd P/E
−1.9×
Dividend yield
—
F-score
3/9
Altman Z
−3.17
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 9.63%

Capital & Financial Ratios $m

Size
Market Cap 376.62
Revenue ttm 117.39
Net income ttm (280.16)
Free cash flow ttm (232.73)
Net debt Q (125.40)
Valuation
P/E 0.00
Forward P/E (1.87) (negative: loss-making)
Price / sales 3.22
Forward P/S Powerpack
Price / FCF 0.00
Price / book 5.05
Financial health
Current ratio Q 4.89 (at or above 1.5: strong)
Debt / equity Q 1.04
Interest coverage Q 16.39
Growth
Revenue growth Q +118.37% (above 0%: growing)
Operating income growth Q +28.39% (above 0%: growing)
EPS, this year +27.43% (at or above 15%: strong)
EPS, next year A +19.47% (at or above 15%: strong)
Revenue, next year A +98.71% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +25.66% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.2×, against a ten-year median of 35.0×; over the ten years it ranged from −27.4× in 2023 to 731× in 2018.
P/S against its own 10 years 0.15%
10-year low 10-year high
P/B against its own 10 years 88.06%
10-year low 10-year high
EV/Sales against its own 10 years 7.35%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 240 589 302 203
Receivables — 0 24 44
Inventory — 4 33 33
Other — — — —
275 661 436 336
2023 2024 2025 Q'26
Payables 0 2 3 1
ST’ Debt — — — —
Other — 4 10 13
45 61 73 69

Compound Annual Growth %

10y 5y 3y
Sales — 113.11% 128.01%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 2.25% (3.24%) (15.83%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.21 Actual −0.15

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.23 −0.30 Miss by 0.07
Q4 FY25 −0.31 −0.34 Miss by 0.03
Q1 FY26 −0.29 −0.27 Beat by 0.02
Q2 FY26 −0.21 −0.15 Beat by 0.06
Q3 FY26 −0.21 — Reports 10 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.27) (0.15) — — —
’25 (0.26) (0.18) (0.30) (0.34) (1.08)
’24 (0.24) (0.22) (0.31) (0.09) (0.86)
’23 (0.23) (0.26) (0.26) (0.44) (1.20)
’22 (0.41) (0.46) (0.47) (0.23) (1.57)
’21 (0.53) (0.47) (0.47) (0.51) (1.97)
’20 (0.60) (0.62) (0.72) (0.82) (2.76)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 26 46 — — —
’25 9 21 21 24 75
’24 10 — — 0 10
’23 1 — 0 0 2
’22 0 — 2 4 6
’21 0 2 0 0 2
’20 0 0 1 0 2
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (65) (25) — — —
’25 (76) (73) (68) (67) (284)
’24 (41) (51) (77) (38) (206)
’23 (42) (38) (40) (25) (146)
’22 (35) (31) (32) (15) (112)
’21 (37) (37) (35) (9) (118)
’20 (24) (27) (39) (28) (118)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (68) (26) — — —
’25 (84) (80) (80) (66) (311)
’24 (41) (52) (86) (62) (241)
’23 (46) (43) (42) (26) (157)
’22 (36) (33) (39) (15) (123)
’21 (39) (38) (39) (11) (127)
’20 (27) (29) (43) (33) (132)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 2 2 1 3 2 2 6 2 10 75 117 +52.5% 150 192 283 +55.5%
Gross margin, % 100.00 0.00 0.00 100.00 100.00 100.00 100.00 100.00 (12.52) (27.83) 15.66 (127.8) pt
EBT (23) (23) (52) (139) (166) (166) (149) (208) (219) (286) (279) +32.1%
EBT margin, % (1,380.98) 0.00 0.00 (4,780.19) (9,694.29) (7,123.95) (2,335.96) (12,273.38) (2,165.36) (378.78) (238.08) +1,002.2 pt
Net income 0 20 0 (124) (142) (142) (149) (208) (221) (288) (280) n/m
Per share, $
Per share, $ Revenue 0.04 0.00 0.00 0.07 0.03 0.03 0.07 0.01 0.04 0.28 0.44 +23.6%
Earnings (0.31) (1.43) (1.42) (2.88) (2.76) (1.97) (1.57) (1.20) (0.86) (1.08) (1.06) +14.9%
Cash flow (0.25) 0.07 (1.00) (2.36) (2.28) (1.64) (1.18) (0.84) (0.81) (1.07) (0.85) +17.7%
Capex 0.00 (0.06) 0.00 (0.43) (0.28) (0.12) (0.11) (0.06) (0.14) (0.10) (0.03) n/m
Free cash flow (0.25) 0.01 (1.00) (2.79) (2.57) (1.76) (1.30) (0.90) (0.94) (1.17) (0.87) +18.9%
Book value 3.55 0.00 7.37 5.92 4.07 4.35 3.14 0.64 1.67 0.67 0.28 (16.9%)
Shares, m 40 51 32 43 52 72 95 174 255 266 266 +23.4%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 0.00 0.00 0.00 195.49 268.76 160.56 27.16 215.42 56.97 7.03 3.22 93.1
P/B 5.05 5.05 4.70 2.23 2.19 1.19 0.59 10.67 1.40 2.97 5.05 3.6
EV/Sales 0.00 0.00 0.00 130.93 208.41 34.33 (28.43) 180.58 5.68 3.90 2.15 53.5
EV/FCF 0.00 0.00 (18.97) (3.16) (2.68) (0.63) 1.50 (6.34) (0.25) (0.91) (0.99) (3.1)
Cash, $m
Cash, $m Operating cash flow (10) 3 (32) (101) (118) (118) (112) (146) (206) (284) (226) +45.3%
Capex (2) (3) (10) (19) (15) (9) (11) (11) (35) (27) (7) +34.7%
Free cash flow (10) 0 (32) (120) (132) (127) (123) (157) (241) (311) (233) +46.7%
Balance, $m
Balance, $m Working capital 137 0 212 224 163 318 379 231 600 362 267 +11.4%
Net debt (137) (137) (217) (188) (104) (294) (364) (192) (540) (302) (125) +9.2%
Shareholders’ equity 143 143 233 255 210 313 299 111 427 178 75 +2.5%
Returns, %
Returns, % ROA (13.27) (58.09) (16.97) (44.41) (47.54) (40.61) (33.23) (48.14) (38.11) (41.92) (46.15) (28.6) pt
ROIC (83.69) 0.00 0.00 (136.01) (98.66) (537.42) 0.00 0.00 0.00 0.00 0.00 +83.7 pt
ROE (41.66) (64.50) (18.34) (50.81) (61.13) (54.30) (48.64) (101.61) (81.91) (94.98) (133.00) (53.3) pt
People
People Employees — 126 166 290 376 324 399 463 647 752 — +25.0%
Revenue/emp, $m 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.00 0.02 0.10 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Autolus Therapeutics PLC Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AVTX Avalo Therapeutics, Inc. $388.8M — (loss-making) — (loss-making) −70.14% (below 0%: shrinking) n/m +75.70% (above 0%: growing) 55.73% 0.00% Compare
RZLT Rezolute, Inc. $387.9M — (loss-making) — — n/m +40.23% (above 0%: growing) 0.00% 0.00% Compare
ALLO Allogene Therapeutics, Inc. $387.0M — (loss-making) — (loss-making) +20,990.91% (above 0%: growing) n/m +17.73% (above 0%: growing) 100.00% (1,011.21%) Compare
ZURA Zura Bio Limited $384.3M — (loss-making) — — n/m −26.22% (below 0%: shrinking) — 0.00% Compare
MPLT MapLight Therapeutics, Inc. $378.5M — (loss-making) — — n/m −31.91% (below 0%: shrinking) — 0.00% Compare
TRXB TRex Bio Inc. $376.8M — — — — — — — Compare
AUTL Autolus Therapeutics PLC Sponsored ADR $376.6M — (loss-making) — (loss-making) +118.37% (above 0%: growing) n/m +67.55% (above 0%: growing) 55.20% (95.95%)
FENC Adherex Technologies Inc. $375.2M — (loss-making) 34.1× +85.18% (above 0%: growing) n/m +101.36% (above 0%: growing) 95.97% 9.72% Compare
TECX Tectonic Therapeutic, Inc. $371.1M — (loss-making) — — n/m −46.69% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $381.4M — — +85.18% — +17.73% 55.73% 0.00%

All 621 Biotechnology stocks →

Autolus Therapeutics PLC Sponsored ADR (AUTL) Latest News

26 Oct

Impact 3 · · GlobeNewswire

5 Oct

Impact 3 · · Zacks
Impact 3 · · GlobeNewswire

12 Sep

Impact 3 ·

9 Sep

Impact 4 ·

11 Aug

Impact 3 · · MarketBeat
Impact 3 ·

3 Aug

Impact 4 ·

24 Jun

Impact 3 · · Simply Wall St.

17 Jun

Impact 4 ·

21 May

Impact 3 · · GlobeNewswire

14 May

Impact 4 · · GuruFocus.com
Impact 4 · · MarketBeat
Impact 3 · · GlobeNewswire

10 May

Impact 4 · · Insider Monkey

4 May

Impact 3 · · Simply Wall St.

29 Apr

Impact 3 · · GlobeNewswire

19 Apr

Impact 3 ·

13 Apr

Impact 4 · · MarketBeat

8 Apr

Impact 4 · · MarketBeat

27 Mar

Impact 4 · · MarketBeat
Impact 4 · · GlobeNewswire

5 Mar

Impact 4 · · MarketBeat

4 Feb

Impact 3 ·

30 Jan

Impact 4 · · Zacks

21 Jan

Impact 3 · · Simply Wall St.

14 Jan

Impact 4 · · Simply Wall St.

13 Jan

Impact 4 · · Simply Wall St.

12 Jan

Impact 4 · · GlobeNewswire

6 Jan

Impact 4 · · GlobeNewswire
stockrow.com/AUTL · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com